Research programme: nanoparticle based radiopharmaceuticals - TAE Life Sciences
Latest Information Update: 28 Jul 2024
At a glance
- Originator TAE Life Sciences
- Class Antineoplastics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Cancer in USA
- 08 Dec 2020 TAE Life Sciences enters into a joint venture agreement with Neuboron Medtech for Accelerator-based Boron Neutron Capture Therapy (AB-BNCT) for the treatment of cancer
- 22 Jun 2020 Nanoparticle based radiopharmaceuticals - TAE Life Sciences is available for licensing as of 22 Jun 2020. https://taelifesciences.com/contact/